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Abstract
Measurement  of  tumor  hypoxia  is  required  for  the  diagnosis  of  tumor  and  the
evaluation of therapeutic outcome. Currently,  invasive and noninvasive techniques
being  exploited  for  tumor  hypoxia  measurement  include  polarographic  needle
electrodes, immunohistochemical (IHC) staining, magnetic resonance imaging (MRI),
radionuclide  imaging  (positron  emission  tomography  [PET]  and  single-photon
emission  computed  tomography  [SPECT]),  optical  imaging  (bioluminescence  and
fluorescence), and hypoxia imaging endoscopy. This review provides a summary of the
modalities available for assessment of tissue oxygenation as well as a discussion of
current arguments for and against each modality, with a particular focus on noninvasive
hypoxia imaging with emerging agents and new imaging technologies intended to
detect molecular events associated with tumor hypoxia.
Keywords: Hypoxia imaging endoscopy, innovation of endoscopy
1. Introduction
In the 1950s, hypoxia research began, and many clinical trials have been reported. Hypoxia of
tumor affects outcomes after radiotherapy. But hypoxia has also been shown to be a poor
prognostic factor after chemotherapy and surgery. These findings are attributed to chronic
hypoxia.  Hypoxic  tumors  are  more  likely  to  recur  loco-regionally  than well-oxygenated
tumors regardless of whether surgery or radiation therapy is the primary local treatment.
However, the common oxygen measurement used in these reports was polarographic needle
electrodes inserted directly into specific sections of tumor tissue. In this method, hypoxia was
measured in only pinpointed area for the tumor. In other words, there was no modality used
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in which the hypoxia imaging results were visible in real time and which reflected the hypoxic
state in the whole tumor. Therefore, hypoxia imaging is expected to allow direct visualization
of the biological and functional changes in cancer.
Hypoxia is a histopathological condition in which cells in tissues suffer from lack of oxygen
for their normal metabolism. An oxygen saturation (StO2) of arterial blood is almost 100% and
that of venous blood is approximately 70%. In contrast, the StO2 in half of cancers is 50–60%
at the highest. Hypoxia takes hold as a tumor becomes large enough to disrupt the balance of
oxygen supply and consumption in the area. Approximately, 50–60% of advanced cancer
forming solid tumor may show hypoxic and/or anoxic conditions exhibiting heterogeneous
distribution in the inside of tumor [1]. Hypoxia proliferates rapidly in solid tumors, and their
intratumoral vessels with significantly structural abnormalities are distributed spatially with
dilated, tortuous, saccular, and heterogeneous figures. As a result, this distribution leads to
perfusion-limited delivery of O2 [2]. There are mainly two types of hypoxia regarding solid
tumor and tissue around tumor. One is perfusion-limited O2 delivery type, the so-called acute
hypoxia, which leads to ischemic condition, however, it is often transient. Another type is
diffusion-limited hypoxia, the so-called chronic hypoxia, which can also be caused by an
increase in diffusion distances, so that cells far away (>70 μm) from a nutritive blood vessel
receive less oxygen (and nutrients) than needed [1]. Regarding hypoxia-induced proteome
and/or genome changes, cell cycle arrest, differentiation, apoptosis, and necrosis are found in
solid tumor. In contrast, hypoxia-induced changes of proteome may progress tumor growth
because of mechanisms enabling cells to overcome nutritive deprivation, to escape from the
hostile environment and to favor unrestricted growth. Furthermore, continuous hypoxia can
also bring cellular changes as a more aggressive phenotype [3]. Since the presence of hypoxic
status in solid tumors was first reported in 1953 to be among the factors associated with
treatment failure following radiation therapy [4], tumor hypoxia has drawn attention as a
pivotal event in tumor invasion, angiogenesis, apoptosis, metastasis [1], resistance to chemo-
therapy [5], surgery, and resistance to radiotherapy [6]. In tumor diagnosis and treatment
planning, it is crucial to have a grasp of the degree and extent of tumor hypoxia involved prior
to the start of treatment.
2. Clinical importance for measurement of tumor hypoxic state
A variety of techniques are being proposed to assess tumor hypoxia, which can be broadly
categorized into direct measurements and indirect measurements according to different
principles and the ability to quantify tissue oxygenation. Direct measurements, including
polarographic needle electrode, phosphorescence imaging, near-infrared spectroscopy
(NIRS), blood oxygen level dependent (BOLD) and 19F magnetic resonance imaging (MRI) and
electron paramagnetic resonance (EPR) imaging, can detect oxygen partial pressure (pO2),
oxygen concentration, or oxygen percentage. Recently, a hypoxia imaging endoscopy that can
derive the oxygen saturation (StO2) was developed in endoscopic fields. Indirect measure-
ments, including measuring exogenous and endogenous hypoxia markers, can provide
parameters related to oxygenation.
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Many clinical trials have been performed using direct and indirect measurement methods. It
is now known that hypoxia affects outcome after radiotherapy, with poor prognosis in hypoxic
cancers. Next, hypoxia has also been shown to be a poor prognostic factor after chemotherapy
and surgery. Furthermore, hypoxic tumors are more likely to recur loco-regionally than well-
oxygenated tumors regardless of whether surgery or radiation therapy was the primary local
treatment.
3. Direct measurements for hypoxia
3.1. Polarographic needle electrodes for direct tumor tissue
The invasive polarographic needle electrodes have been widely employed since the 1990s to
assess tumor oxygen status and to measure pO2 in both human and animal studies [7, 8]. As
the gold standard modality, their use has been extended not only to lymph node metastases
but to more accessible tumors, which include head and neck cancer, cervical cancer, soft tissue
sarcomas of the extremities, astrocytic brain tumors, lung cancer, pancreatic cancer, prostate
cancer, and lymph node metastases [8–12]. With the average median pO2 before treatment of
11.2 mmHg (range 0.4–60 mmHg) [7], these measured values help prediction of the tumor
response to treatment [13] and tumor metastatic potential [14]. The polarographic needle
electrode is currently available under CT guidance for evaluating tumor pO2 in deep-seated
organs as well as for assessing overall tumor oxygen status [15] with the caveat, however, that
insertion of an electrode into the tumor leads to disruption of tissues, thus rendering it difficult
to distinguish the necrotic areas and to establish the patterns of hypoxia involved. Furthermore,
the use of the modality not only calls for great expertise but is associated with large interob-
server variability.
4. Noninvasive imaging of hypoxia
While the polarographic needle electrode and immunohistochemical (IHC) staining can
provide a relatively accurate estimation of tumor oxygenation, being subject to selection bias,
provide only a partial, but not complete, picture of the entire tumor site [16]. This has led to
an increasing interest in the use of noninvasive functional and molecular imaging modalities,
which is capable of yielding a large amount of high-quality experimental data per protocol by
increasing the number of quantitative data collections and by guiding tissue sampling and
allowing a rapid and effective combination of analyses to be conducted [17].
Several imaging modalities have been developed, to date, to allow direct or indirect measure-
ment of tumor oxygenation, with a few of these remaining less mature for clinical application.
Of these, EPR spectroscopy, which involves the use of unpaired electron species to obtain
images and spectra, is currently being explored in animals as a means to provide a quantitative
measure of tissue oxygenation [18]. Although this modality has considerable potential to be
developed as a tumor oximeter, i.e., in monitoring changes after tumor oxygenation [19], a
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suitable paramagnetic marker with low toxicity for human remains yet to become available.
The need for appropriate EPR instrumentation in the clinical setting also prevents this
promising modality from becoming widespread [20]. Photoacoustic tomography (PAT) is also
available for imaging blood oxygenation using the differential optical contrast between O2Hb
and dHb. PAT has been implemented for imaging cerebral blood oxygenation of rats in vivo,
demonstrating that PAT is capable of capturing the changes from hyperoxia to hypoxia [21],
while no study reported on its clinical application.
4.1. Magnetic resonance imaging
BOLD-MRI is shown to have potential as a diagnostic modality for tumor hypoxia [22].
Hemoglobin occurs as deoxyhemoglobin in oxygen-deficient states, where not oxyhemoglobin
but paramagnetic deoxyhemoglobin can increase the transverse relaxation of the surrounding
protons [23]. BOLD-MRI employs deoxyhemoglobin-derived endogenous signals as image
contrast to depict changes in oxygenation in blood. Decreased oxygenation in blood results in
decreased signal intensity in T2-weighted images, and this correlation between the BOLD-MRI
signal and vascular oxygenation allows pO2 to be directly estimated. This has indeed led to
numerous studies being conducted to investigate carbogen breathing in mice, oxygenation in
tumor models [24], and kidney function in patients [22, 25, 26] using the modality as a
noninvasive technique with high spatial and temporal resolution [22]. As with phosphores-
cence and near-infrared fluorescence imaging, the major disadvantage of BOLD-MRI is that it
reflects change in oxygen tension in vasculature but not those in tissues. Again, not being a
quantitative method, it may easily be affected by multiple factors such as flow effects, hema-
tocrit, pH, and temperature [27].
19F MRI involves the use of two types of markers, i.e., perfluorocarbons (PFCs) and fluorinated
nitroimidazoles as contrast agents, which are not used in conventional T1-weighted MRI.
While being highly hydrophobic, PFCs are highly oxygen soluble [28]. Due to the linear
relationship between the 19F spin lattice relaxation rate of PFCs and the dissolved oxygen
concentration, the 19F-based oximetry allows vascular oxygenation to be measured in vivo [29].
PFCs investigated to date include hexafluorobenzene (HFB) [30] and perfluoro-15-crown-5-
ether (PF15C5) [31, 32], which are injectable intravenously or intratumorally. 19F MRI is
increasingly employed to detect changes in tumor oxygenation that occur in response to
treatments that are radio-sensitizing and oxygen-augmenting [33]. The disadvantages of 19F
MRI are that flow artifacts affect the measurements and that, with some contrast agents, oxygen
sensitivity is easily influenced by such conditions as temperature, dilution, pH, common
proteins, and blood [34]. Following intravenous injection, most PFC contrast agent is exten-
sively ingested by the reticuloendothelial system (RES) and their slow clearance may cause
adverse reactions. Their intratumoral injection may also raise concern over its associated risk,
e.g., embolism associated with accidental injection of PFC emulsion into the tumoral vein [35].
One major drawback of the nitroimidazole derivatives is their central nervous system (CNS)
toxicity profile, with misonidazole shown to be associated with neuropathy and acute toxicity
on the CNS [33].
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“Vessel architectural imaging” (VAI) has recently been proposed as a new paradigm in MRI
providing a basis for vessel caliber estimation [36] by incorporating an overlooked temporal
shift in the MR signal, thus generating, unlike any other noninvasive imaging modality, new
information on vessel type and function. Indeed, this new modality allowed an oral pan-
vascular endothelial growth factor (pan-VEGF) receptor kinase inhibitor to be evaluated for
its therapeutic efficacy in glioblastoma patients [37], demonstrating using VAI that anti-VEGF
therapy not only normalizes tumor vasculature and alleviates edema but also prolongs
survival in these patients.
4.2. Positron emission tomography
Efforts have recently been directed toward developing contrast agents for noninvasive hypoxia
imaging with positron emission tomography (PET) and single-photon emission computed
tomography (SPECT). Organic molecular markers labeled with positron-emitting radioiso-
topes are employed in PET imaging to allow the extent of tumor hypoxia to be measured.
Commonly used radioisotopes include 18F, 124I, and 60/64Cu and the molecular markers to be
labeled with these isotopes include 2-nitroimidazoles, e.g., fluoromisonidazole (FMISO), EF5,
and fluoroetanidazole (FETA), nucleoside conjugates, e.g., iodoazomycin arabinoside (IAZA),
and Cu(II)-diacetyl-bis (N4-methylthiosemicarbazone) (Cu-ATSM) [38–40]. These markers are
shown not only to bind maximally to severely hypoxic cells to form such stable adducts as are
detectable with a PET scanner but to provide a clear demarcation of hypoxic cells in vivo
through their rapid reoxidization and removal from normal cells.
Of the first-generation nitroimidazoles, 18F-labeled misonidazole (18F-FMISO) is the most
commonly used as being sensitive only to the presence of hypoxia in viable cells [41]. It is
reported that a hypoxic state defined as <10 mmHg is required to induce significant 18FMISO
uptake [42]. 18F-FMISO uptake is shown to vary widely depending on the type of patients and
tumors, whereas 18 F-FMISO is shown to allow hypoxia to be detected in various tumors such
as glioma, head and neck cancer, renal tumor, and non-small cell lung cancer [42–44]. A clinical
trial of glioblastoma multiforme patients [45] demonstrated increased 18F-FMISO uptake and
retention on both post-treatment FMISO and FDG images, suggesting that reoxygenation did
not take place. It is reported that the distribution of oxygen and hypoxia was increased and
decreased, respectively, in non-small cell lung carcinomas following treatment, as assessed by
sequential FMISO imaging [46]. Given that no correlation is shown between patient diagnosis
and degree of decrease in FMISO uptake and retention, in selectively boosting the radiation
dose to hypoxic subvolumes, there appears to be a larger role for serial imaging during
treatment than for baseline volume measurement. Again, pretreatment FMISO uptake/
retention and survival has been shown to be correlated and allow treatment failure to be
predicted [45, 47]. However, 18F-FMISO may not be readily available for use in other cancers
[42, 48].
The second-generation nitroimidazoles include 18F-fluorerythronitroimidazole (FETNIM)
[49, 50], FETA [51], and EF5 [52, 53], which are more water soluble and not readily suscepti-
ble to degradation by most oxidizing mechanisms in place in humans. 18F-EF5 was tested in
clinical trials for its feasibility as an imaging agent for hypoxia [54] and was shown to be
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hypoxia-specific, with its increased uptake shown to be correlated with the extent of tumor
and high risk of metastasis in cancer patients [52], suggesting its usefulness in identifying
high-risk candidates for clinical trials evaluating the influence of early chemotherapy on the
occurrence of metastasis [55]. 18F-FAZA has great promise as an imaging agent for tumor
hypoxia due to its faster diffusion into cells and faster clearance from normal tissues than
18F-FMISO [56]. PET imaging using 18F-FMISO demonstrated very high tracer uptake in all
seven patients with high-grade gliomas evaluated, showing the potential of 18F-FMISO as
an imaging agent in assessing hypoxia in this tumor type [57].
4.3. Phosphorescence imaging
Phosphorescence imaging with injection of porphyrin complex (Oxyphor) into the vasculature
also allows tumor vascular pO2 to be measured [58, 59]. Recently, a general approach has been
proposed through which to construct phosphorescent nanosensors with tunable spectral
characteristics, varying degrees of quenching, and a high oxygen selectivity [60]. These probes
are shown to exhibit excellent performance in measuring vascular pO2 in the rat brain with in
vivo microscopy [60]. NIRS are also available for analysis of tumor oxygenation in vivo based
on recorded spectral changes by hemoglobin in the vasculature [61–63]. Kim and Liu [64]
demonstrated in an animal study that NIRS is associated with comparable efficacy to that with
electrode measurements in evaluating tumor hypoxia. They showed that either carbogen
(95% CO2 and 5% O2) or 100% oxygen inhalation could improve the vascular oxygen level of
rat breast tumors. However, both phosphorescence imaging and NIRS are not readily trans-
latable into clinical applications due to their low spatial resolution, light scattering, limited
path length, low sensitivity, and susceptibility to environmental influence.
4.4. Visible light spectroscopy
In the search for noninvasive, continuous modalities for monitoring ischemia, electrical
bioimpedance cardiac output monitoring has been proposed but shown to be incompatible
with the thermodilution methods [65, 66]. Again, while near-infrared spectroscopy (NIRS) [67]
is shown to respond to both hypoxemia [68, 69] and ischemia [70–72], its clinical use has been
limited to large organs, such as the brain [73, 74, 85–87] with its broad normal ranges reported
to be between 48% and 88% [75, 76]. Similarly, wide normal ranges are reported for sublingual
capnography [77–79]. Also available, albeit invasive are polarographic oximetry probes [80]
and fiber-enabled pulmonary catheters.
Visible light spectroscopy (VLS) appears to be similar to NIRS on some counts [81] with its
mean VLS StO2 shown to be not significantly different from NIRS StO2 reported in human
studies [67–76]. Again, the fractional contribution of venous blood to the cerebral NIRS signal
has been reported to be 0.84 ± 0.21 ranging from 0.60 to 1.00 [82–84]. Using central venous and
pulse oximetry saturation as estimates for local venous and arterial saturation, it is shown to
be not significantly different at 0.89 ± 0.04. It is suggested that the two modalities cover similar
microvascular compartments.
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At the same time, VLS is shown to be superior to NIRS in monitoring tissues that lend
themselves to monitoring, thus suggesting a more versatile role for VLS in patient treatment
[81]. The NIRS light sources and detectors require to be spaced 2–5 cm apart or more to
illuminate and monitor a large, homogenous tissue volume (>30 ml), thus making NIRS with
its long and bulky sensors unsuitable for monitoring tissue regions, e.g., thin tissues such as
gastrointestinal mucosa or small tumors. In contrast, the visible light used in VLS is shown to
be strongly absorbed by tissue and VLS measurement to be highly localized thus making VLS
unsuitable for transcranial use or use over thick skin dominated by surface tissue properties.
Using VLS, a rapid real-time drop in tumor oxygenation was detected during local ischemia
following clamping or epinephrine administration [85], with the tissue oximetry performed
during endoscopy demonstrating a significantly lower tissue oxygenation (StO2) in tumors
(46% ± 22%) than in normal mucosa (72% ± 4%) (P < 0.0001). Thus, VSL tissue oximetry may
be able to distinguish neoplastic tissue with a high specificity to aid in the endoscopic detection
of gastrointestinal tumors. Again, of note, chronic gastrointestinal ischemia was also detected
using the same method [86] (Figure 1).
Figure 1. VLS measurements using a fiber-optic catheter-based VLS oximeter. The catheter is passed through the acces-
sory channel of the endoscope and positioned about 1–5 mm above the mucosa.
5. Hypoxia imaging endoscopy with no phosphor
Kaneko et al. [87] reported hypoxia imaging endoscopy equipped with a laser light source. In
this system, signals from the laser light passed through the processor were calculated as StO2.
The measurement range of StO2 was from 0% to 100% in contactless of tumor or normal mucosa
under endoscopic observation. Display imaging was performed with the use of laser light alone
without phosphor, provided a display of overlay and pseudocolor images. The laser light used
was not near-infrared but ranged within visible light wavelengths. In principle, this utilized
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the difference in absorption coefficient between oxyhemoglobin and deoxyhemoglobin. Two
challenges were identified, however, in deriving the StO2 of tissue in alimentary tracts from
differences in absorption spectra between oxyhemoglobin and deoxyhemoglobin using small
numbers of wavelengths. First, there is not only a small difference in optical absorption spectra
in the visible light region but also a narrow bandwidth between isosbestic points. Second, the
reflectance of a tissue depends on hematocrit (Hct) as well as StO2, given that light absorption
increases as hemoglobin density increases.
An imaging system equipped with laser diodes of 445 and 473 nm and a white fluorescent
pigment body was therefore developed. Hypoxia imaging with this system rendered visible
an alimentary tract tumor in real time and allowed the whole tumor to be visualized. With the
tumor surface and normal mucosa rendered visible, no heterogeneity was seen with the use
of this system. In the first-in-human clinical trial, early cancers of the esophagus, stomach, and
colorectum were detected as hypoxic areas (Figure 2). Furthermore, colorectal adenomas with
histologically low-grade atypia were also detected as hypoxic areas and no complications were
reported in the patients with visualization of these tumors in real-time hypoxia imaging which
involved only laser light without injection or oral administration of phosphor. As mentioned
above, it will be expected that the hypoxia imaging endoscopy is shown to be superior to VLS
or NIRS in measuring StO2 of surface of tumor and normal mucosa.
Figure 2. StO2 maps obtained in human subject research. (A) White light image by endoscopic observation in rectal
adenocarcinoma (left). Line (L-R) corresponds to cross section of pathological diagnosis. StO2 map visualized by laser
endoscope system (middle: pseudocolor StO2 image; right: StO2 overlay image). (B) Cross-sectional appearance stained
with H&E (upper) and HIF1 alpha antibody (lower) corresponding to the hypoxic area visualized with StO2 map. (C)
Endoscopic images of a colorectal adenoma (upper) showing clear hypoxia: white light image (upper left), pseudocolor
StO2 map (upper middle) and overlayed image (upper right). Another case of a colonic lesion (lower) consisting of an
adenoma (red arrow) and a hyperplasia (blue arrow): white light image (lower left), pseudocolor StO2 map (lower mid-
dle) and overlayed image (lower right). Only the adenoma was detected as hypoxia.
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6. Indirect hypoxia evaluation
Proteins and genes whose expression is associated with hypoxia have potential as endoge-
nous molecular markers of hypoxia and have been explored over the years; meanwhile,
hypoxia-specific agents have also been explored and shown to be useful in monitoring
hypoxia [88]. Immunohistochemical (IHC) staining for hypoxia marker adducts in situ is also
available to provide indirect quantitative information on the relative oxygenation of tissue
at a cellular resolution. IHC approaches have a role to play particularly in vitro studies,
including assays of human biopsy specimens. Given the complex biology of tumor hypoxia
for which no single marker is expected to have a strong prognostic power in clinical practice,
efforts have been directed toward combining various markers to create a prognostic profile
of hypoxia [89].
6.1. Hypoxia-inducible factor 1
Optical imaging has had an important role to play in evaluating hypoxia, especially in biopsy
specimens. With the introduction of transgenes with the hypoxia responsive element as
promoter sequences coupled to reporter genes, e.g., luciferase reporter gene [90, 91] or green
fluorescent protein (GFP) [92], a number of modalities have been developed to allow HIF-1
activity to be directly measured. Of these, a HIF-1-dependent promoter-regulated luciferase
reporter gene, shown to produce a 100-fold increased luciferase response to hypoxia, has been
used to evaluate anti-hypoxia therapy for its efficacy in animals [93]. Again, an imaging probe
has been developed for HIF-1-active cells using a PTD-ODD fusion protein. given that, being
involved in the same ODD control as HIF-1α, PTD-ODD fusion proteins are thought likely to
be co-localized with HIF-1α [93–96]. First developed as a model probe, PTD-ODD-enhanced
GFP-labeled with near-infrared fluorescent dye Cy5.5 was shown to permeate cell membrane
with high efficiency, with its stability controlled in an oxygen concentration-dependent
manner; to accumulate in hypoxic tumor cells with HIF-1 activity, thus allowing the hypoxic
tumor cells with HIF-1 activity to be imaged in contrast to the surrounding cells under aerobic
conditions [96]. Bioluminescence imaging has also been used to noninvasively depict HIF-1α
as it is upregulated in vivo following chemotherapy, suggesting that this modality may prove
useful in the evaluation of emerging anti-HIF-1 therapeutics [97]. While these imaging tools
have a role to play in elucidating the biology of hypoxia and mechanisms of tumor response
to therapy, heterogeneous gene responses to HIF-1 pose challenges to these HIF-1-targeted
modalities. Furthermore, only weak correlation has been shown between HIF-1α expression
and oxygen electrode or PET imaging measurements [98, 99], thus throwing in doubt the value
of HIF-1α quantification as a measure of hypoxia.
6.2. Carbonic anhydrase IX
Downstream of HIF-1, carbonic anhydrase 9 (CA IX), a member of the CA family known to
exist in cytosolic, membrane-associated, mitochondrial, and secreted carbonic anhydrases
(CAs), may represent an alternative target [100]. A membrane-associated enzyme involved
in the respiratory gas exchange and acid-base balance, CA IX is shown to be found less
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abundantly in normal tissue and only in gastric mucosa, small intestine, and muscle. Under
hypoxic conditions, CA IX is shown to be overexpressed in different types of cancer [101],
with the staining pattern shown to be more generalized in VHL-associated tumors and focal-
perinecrotic in non-VHL-associated tumors [102].
CA IX has been imaged with fluorescent-labeled sulfonamides in a tumor xenograft model to
allow hypoxic and (re)-oxygenated cells to be distinguished [103], which demonstrated that
CA IX required exposure to hypoxia for its binding and retention—a finding confirmed by an
in vivo imaging study [103]. In renal-cell carcinoma xenografts, a G250 monoclonal antibody
against CA IX was shown to significantly inhibit tumor growth [104]. Again, phase II clinical
trials employed G250-based radioimmunoimaging to detect primary and metastatic lesions as
well as to guide radioimmunotherapy after labeling G250 with therapeutic radioisotopes,
which included 177 Lu, 90 Y, or 186 Re [105]. High-affinity human monoclonal antibodies (A3 and
CC7) specific to human CA IX were developed using phage display technology [106] and these
reagents may have a role to play in a wide range of settings, including noninvasive imaging
of hypoxia and drug delivery [106]. In this regard, combining CA IX and a proliferation marker
may prove helpful in identifying proliferating cells under hypoxic conditions [107, 108], while
no correlation is shown between the amount of CA IX and direct oxygen measurement with a
needle electrode [109].
Furthermore, hypoxia markers have been identified and shown to be induced by hypoxia
and expressed in human tumors, including VEGF and GLUTs, both of which are upregulated
by increased activity of HIF-1 under hypoxic conditions [110]. Imaging strategies targeting
these proteins have also been explored for their ability to assess tumor vasculature and
proliferation, while the relationship between pO2 values and protein expression levels
remains unclear [111].
7. Heterogeneity of tumor
Tissue oxygenation is shown to be highly heterogeneous due to the presence of both highly
oxygenated arterial vascular regions and poorly oxygenated tissues and cells. Spatial and
temporal heterogeneity also contribute to the complexity of the issue. Heterogeneity is thus a
major factor in hypoxia measurement that affects our ability to stratify patients and predict
outcomes using the imaging technologies available, and its biological implications need to be
further explored, and effective approaches to assessing heterogeneity remain to be established.
Hypoxia imaging endoscopy allowed early cancers of the pharynx, esophagus, stomach, and
colorectum to be captured in whole for the first time [87], with no heterogeneity found in nearly
all early cancers or colorectal neoplasia detected. Given that tissue heterogeneity may vary
between early, advanced, and metastatic tumors, however, it remains crucial to elucidate tissue
heterogeneity as it is associated with tumor progression.
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8. Future of hypoxia measuring methods
Given the wide variety of techniques available for assessing hypoxia, e.g., polarographic needle
electrodes, IHC staining, PET, MRI, optical imaging with NIR fluorescence or bioluminescence,
visible light spectroscopy, and hypoxia imaging endoscopy, it remains critically important to
determine their relative advantages and disadvantages for clinical application. Improvements
in hypoxia measuring techniques will hinge primarily on which techniques are chosen and
how these techniques are applied in the clinic. Clearly, the best of these are expected to be
sensitive to the biological sequel of hypoxia, and the ideal one expected to be clinically safe,
readily available, minimally invasive, and free from radiation exposure, while at the same time
providing high resolution and ease of use. In addition, NIR over 1000 nm wavelength, the so-
called biological window, will be promising, because this wavelength area is good for tissue
permeability due to reducing both light scattering and infrared absorption [112].
In the endoscopic fields of alimentary tracts, the existing diagnosis for neoplasia is based on
the morphologic features of the tumor. However, imaging of a tumor focused on its function
or metabolism yields a novel set of data. Hypoxia imaging endoscope system equipped with
a laser source allows oxygen saturation to be shown with two types of overlay and pseudocolor
images displayed one on top of the other [87]. Available for handling similarly to conventional
endoscopy, this modality is easy to treat with and completely safe without being invasive. Of
the large number of patients with cancers in the alimentary tract, such as oral cavity, esophagus,
stomach, and colorectum in the world, a majority with advanced cancer patients receives
chemotherapy, radiotherapy, and combination therapy. In this regard, this modality is expected
to allow not only hypoxic states but also hyperoxic states of tumor to be detected in these
patients, thus contributing to selection of therapy or drug as well as evaluation of their
therapeutic efficacy. Furthermore, this modality will serve as a screening method facilitating
detection of early cancer. Advances in research into hypoxia and intratumoral microvessels of
tumor with this endoscopic modality are expected and lead to development of new drugs.
Thus, the proposed laser source-equipped hypoxia endoscope system appears to have the
potential to redraw the endoscopic landscape.
9. Conclusions and perspectives
Tumor hypoxia assessment allows cancer patients to be followed up early after treatment
initiation and drug resistance and radioresistance to be predicted. Current insights into the
molecular mechanisms of hypoxia have indeed led to novel probes being developed for
noninvasive imaging of hypoxia. Again, real-time hypoxic imaging in digestive endoscopy
was obtained using such laser light as remains within visible light wavelengths, with no use
of any probes. For innovation of endoscopy, it was elucidated that most of all early cancers and
precursor lesions have already been to hypoxic state. This is a cutting edge finding. This
imaging technology highlights a novel aspect of cancer biology as a potential biomarker which
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may come to be widely used in cancer diagnosis and treatment effect prediction. These
approaches appear to have great promise and further studies on the predictive value of hypoxia
measurement in tumors may help identify independent predictive marker of hypoxia as well
as optimal parameters for assessing hypoxia. It remains to be clarified whether these new
agents may help reduce hypoxic disease or whether they are available for hypoxia imaging.
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